The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference

Monday, December 20, 2010

Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference06:30 EST Monday, December 20, 2010ANAHEIM, Calif., Dec. 20, 2010 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the 29th Annual J.P. Morgan Healthcare Conference at 12:00 p.m. PT on Thursday, January 13, 2011 at the Westin St. Francis Hotel in San Francisco, California. Don M. Bailey, President and Chief Executive Officer, will review the Company's business strategy and recent corporate developments.A live audio and slides webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available for 90 days after the live presentation, and can also be accessed at www.questcor.com. About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor markets H.P. Acthar® Gel (repository corticotropin injection), which is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders.  Questcor also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com. SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey of Questcor Pharmaceuticals, Inc., +1-510-400-0776, dbailey@Questcor.com; or Investors, Gregory Gin or Doug Sherk, +1-415-896-6820, or Media, Janine McCargo, +1-646-688-0425, all of EVC Group for Questcor Pharmaceuticals, Inc.